AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06205979
Drug: Ranibizumab Injection [Lucentis]
RxNorm normalized name: ranibizumab Injection [Lucentis]
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Three consecutive monthly intravitreal injections of Ranibizumab at a dosage of 0.5mg/0.05ml were administered in a sterile manner using a 30-G needle toward the center of the vitreous at 4mm in phakic or 3.5mm in pseudo phakic eyes from the limbus.
Trial: NCT05705505
Drug: Narazaciclib
RxNorm normalized name: Narazaciclib
DrugBank: Narazaciclib (DB19038)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orange tablets, each containing 40 mg or 120 mg of narazaciclib as narazaciclib monolactate
Trial: NCT05705505
Drug: Letrozole 2.5mg
RxNorm normalized name: LETROZOLE 2.5MG TAB
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT06205979
Drug: Aflibercept Injection [Eylea]
RxNorm normalized name: aflibercept Injection [Eylea]
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Three consecutive monthly intravitreal injections of Aflibercept at a dosage of 2mg/0.05ml were administered in a sterile manner using a 30-G needle toward the center of the vitreous at 4mm in phakic or 3.5mm in pseudo phakic eyes from the limbus.
Trial: NCT05633563
Drug: Trimetazidine
RxNorm normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral intake of capsules
Trial: NCT05139043
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV and PO
Trial: NCT05110638
Drug: SKX-16 (Luliconazole 10% Solution)
RxNorm normalized name: luliconazole 10 MG/ML
DrugBank: Luliconazole (DB08933)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SKX-16 (Luliconazole 10% Solution) will be applied to each toenail and periungual areas once daily for 29 days such that there is sufficient quantity of solution to treat all toenails. All ten toes will be treated regardless of whether affected. The applications will occur in the clinic and be applied by study personnel. The nails will remain exposed until the applied solution dries.
Trial: NCT00000995
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000995
Drug: Ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04907682
Drug: Ribavirin iv
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 mg/kg Day 1 (dose is divided: 2/3 stat, 1/3 8 hours later, maximum dose is 7g/day), then 25 mg/kg days 2-7, 12.5 mg/kg days 8-10
Trial: NCT04907682
Drug: Favipiravir
RxNorm normalized name: favipiravir
DrugBank: Favipiravir (DB12466)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Day 1 2400mg(H0)-2400mg(H8)-1200mg(H16), Day 2-10 1200mg twice daily
Trial: NCT00049790
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00049790
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT06354140
Drug: Tegafur
RxNorm normalized name: tegafur
DrugBank: Tegafur (DB09256)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Tegafur (S-1) 80mg/100mg/120mg Q3W (discontinued at the third week) + tislelizumab 200 mg Q3W, treatment for 1 year. Tegafur: body surface area (BSA) \< 1.25m2, use 80mg; 1.25-1.5m2, use 100mg; \> 1.5m2, use 120mg. Treatment for 1 year
Trial: NCT05640180
Drug: Finerenone (Kerendia, BAY94-8862)
RxNorm normalized name: Finerenone
DrugBank: Finerenone (DB16165)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Retrospective cohort analysis using randomized clinical trials data.
Trial: NCT05640180
Drug: Sodium-glucose cotransporter-2 inhibitors (SGLT2i)
RxNorm normalized name: glucose / sodium chloride
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Retrospective cohort analysis using United States Optum Electronic Health Records data.
Trial: NCT00121017
Drug: Kaletra (lopinavir/ritonavir)
RxNorm normalized name: lopinavir / ritonavir Oral Tablet [Kaletra]
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00121017
Drug: Sustiva (efavirenz)
RxNorm normalized name: efavirenz Oral Capsule [Sustiva]
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00121017
Drug: Truvada (emtricitabine/tenofovir disoproxil fumarate)
RxNorm normalized name: Truvada
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05239650
Drug: HLX07
RxNorm normalized name: Lanraplenib
DrugBank: Lanraplenib (DB14770)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000mg
Trial: NCT05239650
Drug: HLX10
RxNorm normalized name: Immunoglobulin g4 (228-proline), anti-(human programmed cell death protein 1) (human-mus musculus monoclonal hlx10 .gamma.4-chain), disulfide with human-mus musculus monoclonal hlx10 .kappa.-chain, dimer
DrugBank: Serplulimab (DB17451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg
Trial: NCT04853758
Drug: Sacubitril / Valsartan Oral Tablet [Entresto]
RxNorm normalized name: sacubitril / valsartan Oral Tablet [Entresto]
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 100 consecutive participants randomized independently at the Heart Institute - School of Medicine of the University of São Paulo (InCor),will receive sacubitril/valsartan for 6 months.
Trial: NCT04853758
Drug: Enalapril
RxNorm normalized name: Enalapril
DrugBank: Enalapril (DB00584)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 consecutive participants randomized independently at the Heart Institute - School of Medicine of the University of São Paulo (InCor),will receive enalapril for 6 months.
Trial: NCT05715840
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 175 mg/m\^2，Q3W，IV infusion
Trial: NCT05715840
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/m\^2，Q3W，IV infusion
Trial: NCT05715840
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AUC=5，Q3W，IV infusion
Trial: NCT05715840
Drug: Bevacizumab injection
RxNorm normalized name: bevacizumab Injection
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 15 mg/kg，Q3W，IV infusion
Trial: NCT06285149
Drug: Icaritin
RxNorm normalized name: Icaritin
DrugBank: Icaritin (DB12672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This product is suitable for patients with unresectable hepatocellular carcinoma who are not suitable for or refuse to receive standard treatment and have not received systemic treatment in the past, and the peripheral blood compound markers of patients meet at least two of the following detection indicatorsItem: AFP\>400 ng/mL; TNF-a\<2.5 pg/mL; IFN-y\>7.0 pg/mL.The conditional approval is based on data from an interim analysis of an enriched population in a randomized controlled Phase 11 clinical trial, and full approval for this indication will be subject to confirmation of the clinical benefit of the product in planned confirmatory trials.
Trial: NCT05715398
Drug: BR790+anlotinib
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BR790 will be administered orally, variable dose on Day 1 of each 21-day cycle， Anlotinib will be administered as PO fixed dose on Day1-14 of each 21-day cycle
Trial: NCT00000235
Drug: Buprenorphine
RxNorm normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT06033118
Drug: gemcitabine ,oxaliplatin,anlotinib,Sintilimab
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemox chemotherapy（gemcitabine 1g/m2 ivgtt d1,d8 +oxaliplatin 85g/m2 ivgtt d1，q3w，anlotinib (8mg po d1-14 q3w )and Sintilimab (200mg ivgtt d1 q3w)
Trial: NCT06371170
Drug: Rivaroxaban
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral anticoagulation
Trial: NCT05859776
Drug: AXT107 Low Dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single suprachoroidal injection of AXT107 (0.125 mg/eye)
Trial: NCT05859776
Drug: AXT107 High Dose
RxNorm normalized name: HIGH DENSITY POLYETHYLENE
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single suprachoroidal injection of AXT107 (0.500 mg/eye)
Trial: NCT04723394
Drug: AZD7442
RxNorm normalized name: AZD7442
DrugBank: AZD7442 (DB15787)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose (× 2 separate IM injections) of 600 mg of AZD7442 or saline placebo on Day 1.
Trial: NCT05355064
Drug: Trehalose
RxNorm normalized name: Trehalose
DrugBank: Trehalose (DB12310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enrolled subjects will daily take 4 g of trehalose in oral administration for 24 weeks.
Trial: NCT05930119
Drug: Rabeprazole
RxNorm normalized name: Rabeprazole
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg of rabeprazole will be administered by mouth once daily.
Trial: NCT04979052
Drug: Interferon Gamma-1B
RxNorm normalized name: Interferon Gamma-1B
DrugBank: Interferon gamma-1b (DB00033)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 microgram per day, three times a week, subcutaneous. The duration of the treatment is twelve days or until hospital discharge.
Trial: NCT04989140
Drug: Drug: Ixazomib Drug:pomalidomide Drug:dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Treatment was continued until disease progression, unacceptable toxicity
Trial: NCT06247046
Drug: Live SK08 powder
RxNorm normalized name: Vibrio cholerae CVD 103-HGR strain live antigen
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Powder
Trial: NCT00038454
Drug: Hemolink (hemoglobin raffimer IV solution)
RxNorm normalized name: hemoglobin raffimer
DrugBank: Hemoglobin raffimer (DB13658)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06314763
Drug: Rivaroxaban 20mg
RxNorm normalized name: RIVAROXABAN 20MG TAB
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single dose on day 1 and day 16
Trial: NCT06314763
Drug: Sotorasib 960mg
RxNorm normalized name: sotorasib
DrugBank: Sotorasib (DB15569)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daily dose from day 3 till day 16
Trial: NCT01255501
Drug: NI-0701
RxNorm normalized name: Toto ni vavalagi oil
DrugBank: Castor oil (DB11113)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04702256
Drug: Obinutuzumab administration
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Obinutuzumab administration by intravenous infusion (IV), IV of methylprednisolone, oral mycophenolate mofetil, no prednisone (or if required for extrarenal manifestation(s): less than 10mg/day at any time, less than 7.5mg/day after 6 months and less than 5mg/day after 9 months).~Hydroxychloroquine will be strongly recommended for all the patients.
Trial: NCT04702256
Drug: Administration of Methylprednisolone + Prednisone + Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV of methylprednisolone, oral prednisone (according to the PNDS), and oral mycophenolate mofetil.~Hydroxychloroquine will be strongly recommended for all the patients.
Trial: NCT00298285
Drug: enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05872685
Drug: S1
RxNorm normalized name: LS11
DrugBank: LS11 (DB05918)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 orally intake as perioperative chemotherapy
Trial: NCT05872685
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin (130 mg/m2) infusion as perioperative chemotherapy
Trial: NCT05872685
Drug: Serplulimab
RxNorm normalized name: Serplulimab
DrugBank: Serplulimab (DB17451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative serplulimab, 300 mg IV infusion
Trial: NCT00002044
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04752631
Drug: Tenecteplase
RxNorm normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The participants received TNK-tPA thrombolytic therapy
Trial: NCT05761405
Drug: Ceftriaxon
RxNorm normalized name: Ceftriaxone
DrugBank: Ceftriaxone (DB01212)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preselected patients with ureteral stents in situ who are scheduled to undergo endourological ureteral stent manipulation will have routine urine cultures prior to intervention.~Procedures: Consented patients will be randomized for the type of antibiotic prophylaxis according to a global randomization list (i.e. CRO, AMK, AMK1/2+MAN)).~Antibiotics will be delivered in a single infusion that will be administered within 30 minutes.
Trial: NCT06419985
Drug: 80mg Ketamine HCl Prolonged Release
RxNorm normalized name: Ketamine Hydrochloride
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of Ketamine HCl Prolonged Release - 80mg
Trial: NCT06419985
Drug: 160mg Ketamine HCl Prolonged Release
RxNorm normalized name: Ketamine Hydrochloride
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of Ketamine HCl Prolonged Release - 160mg
Trial: NCT06419985
Drug: Administration of Ketamine HCl Prolonged Release - 240mg
RxNorm normalized name: Ketamine Hydrochloride
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of Ketamine HCl Prolonged Release - 240mg
Trial: NCT04761601
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine injection for intravenous use.
Trial: NCT04761601
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel protein-bound particles for injectable suspension (albumin-bound).
Trial: NCT00663624
Drug: aspart insulin
RxNorm normalized name: Aspart Insulin
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: subcutaneous aspart insulin every 2 hours
Trial: NCT05933213
Drug: Mescaline sodium enteric-coated tablets
RxNorm normalized name: diclofenac
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Induction period: orally, twice a day, at 720-1440 mg/d； Maintenance period: orally, twice a day, 360-540mg/d
Trial: NCT05933213
Drug: Morte-mescaline
RxNorm normalized name: Mescaline
DrugBank: Mescaline (DB19083)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction period: orally, twice a day, 1-2 g/d; Maintenance period: orally, twice a day, 0.5-0.75 g/d
Trial: NCT05188118
Drug: Cabozantinib
RxNorm normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 60mg oral once daily for 12 weeks
Trial: NCT05188118
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1mg/kg intravenous once every 3 weeks over 12 weeks
Trial: NCT05188118
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 3mg/kg intravenous once every 3 weeks over 12 weeks, then 480mg once every 4 weeks after
Trial: NCT05188118
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 18mg oral once daily for 12 weeks
Trial: NCT05188118
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5mg oral once daily for 12 weeks
Trial: NCT05101447
Drug: Mycophenolate Mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: At baseline, subjects will be randomized 1:1 to one of two treatment arms: the current standard of clinical care \[MMFBSA: 600 mg/m2/dose; max: 3 gram/day\] or pharmacokinetically-driven precision dosing \[MMFPK: 12-hour target area under the exposure curve of MPA (MPA-AUC0-12) at 60 mg\*h/L\].
Trial: NCT04951115
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AUC = 5-6 mg/mL per min on Day 1 of each 21-day cycle, for 4 cycles
Trial: NCT04951115
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75-80 mg/m2 on Day 1 of each 21-day cycle, for 4 cycles
Trial: NCT04951115
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 80-100 mg/m2 on Day 1, Day 2, and Day 3 of each 21-day cycle, for 4 cycles
Trial: NCT04481672
Drug: Magnesium Sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous infusion of magnesium sulfate prior to intraoperative chemotherapy with cisplatin.
Trial: NCT04951115
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1500 mg on Day 1 of each 21-day cycle, for 4 cycles. Following this, 1500 mg once every 4 weeks until disease progression
Trial: NCT06307301
Drug: Abatacept Injection [Orencia] and Proleukin (aldesleukin)
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Abatacept (Orencia®) and recombinant human IL-2 (aldesleukin). Patients will receive a fixed dose of subcutaneous abatacept (125 mg/mL) at day 1. Two weeks later (day 15), patients will receive the second dose of subcutaneous abatacept (125 mg/mL). In addition, patients will receive subcutaneous IL-2 (1x106units /day) for 5 days (days 15-19). If this treatment regimen is tolerated, patients will receive 28 further similar treatment courses of abatacept and IL-2 every two weeks.
Trial: NCT06133049
Drug: Ozanimod
RxNorm normalized name: Ozanimod
DrugBank: Ozanimod (DB12612)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Women with MS who were exposed to ozanimod during pregnancy
Trial: NCT06133049
Drug: Select DMTs other than ozanimod
DrugBank: Ozanimod (DB12612)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Women with MS exposed to select DMTs other than ozanimod during pregnancy
Trial: NCT04337177
Drug: VAL-413
RxNorm normalized name: Val
DrugBank: Valine (DB00161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: a flavored preparation of orally administered irinotecan
Trial: NCT04337177
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: alkylating oral chemotherapy agent used to treatment brain cancers
Trial: NCT05098028
Drug: Low Dose Rifaximin ER
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low Dose Rifaximin Extended Release Twice Daily
Trial: NCT05098028
Drug: Low Dose Rifaximin DER
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low Dose Rifaximin Delayed Extended Release Twice Daily
Trial: NCT05098028
Drug: High Dose Rifaximin ER
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High Dose Rifaximin Extended Release Twice Daily
Trial: NCT05098028
Drug: High Dose Rifaximin DER
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High Dose Rifaximin Delayed Extended Release Twice Daily
Trial: NCT05124067
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: patients will receive dexamethasone (0.15 mg/kg IV; maximum 5 mg)
Trial: NCT05124067
Drug: Ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients will receive ondansetron (0.05 mg/kg IV; maximum 4 mg)
Trial: NCT05124067
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive dexmedetomidine (0.3 μg/kg)
Trial: NCT05498792
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patient will be on Ipilimumab (1 mg/kg)
Trial: NCT05498792
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patient will be on Nivolumab (3 mg/kg)
Trial: NCT06472661
Drug: PolyICLC
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PolyICLC (polyinosinic-polycytidylic acid that is stabilized with carboxymethylcellulose and polylysine) is a drug that may help the body build an effective immune response to kill tumor cells. A single injection of .9 mg of polyICLC into one tumor will be given within 4 hours after the FUSA.
Trial: NCT04819464
Drug: Cenerimod
RxNorm normalized name: Cenerimod
DrugBank: Cenerimod (DB12705)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose of 0.5 mg.
Trial: NCT05095636
Drug: Apatinib Mesylate
RxNorm normalized name: mesylate
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral Apatinib once everyday
Trial: NCT05095636
Drug: Camrelizumab
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous camrelizumab 200mg once every two weeks